Efficacy of Pulsed Electromagnetic Field Therapy on Women With Endometriosis
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Pulsed Electromagnetic Field Therapy, Sham pulsed electromagnetic field therapy.
- Who it may be relevant to
- Registry conditions: Endometriosis, Pulsed Electromagnetic Therapy, Trans Perineal Ultrasound. Basic parameters: 18 years — 45 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Efficacy of Pulsed Electromagnetic Field Therapy on Women With Endometriosis, A Randomized Controlled Trial
Overview
This randomized, sham-controlled, double-blinded clinical trial aims to investigate the effects of pulsed electromagnetic field therapy (PEMF) on pain intensity, quality of life, and pelvic floor morphometric changes assessed by four-dimensional trans perineal ultrasound (4D TPUS) in women diagnosed with endometriosis. Participants will be randomly allocated into either a PEMF therapy group or a sham PEMF control group. Both groups will continue receiving stable standard medical care throughout the study period. Assessments will be conducted at baseline, after completion of the 8-week intervention period, and at 3-month follow-up.
Detailed description
Endometriosis is a chronic inflammatory gynecological disorder characterized by ectopic endometrial tissue growth and commonly associated with chronic pelvic pain, dysmenorrhea, dyspareunia, and impaired quality of life. Myofascial dysfunction and pelvic floor muscle hypertonia are increasingly recognized as contributing factors to persistent pain and pelvic floor dysfunction in women with endometriosis. Pulsed electromagnetic field therapy (PEMF) is a non-invasive physical modality with reported analgesic, anti-inflammatory, and tissue-healing effects in musculoskeletal and chronic pain disorders. However, evidence regarding its use in women with endometriosis remains limited. Therefore, this study aims to evaluate the effectiveness of PEMF therapy on pain severity, disease-specific quality of life, and pelvic floor morphometric changes assessed using four-dimensional trans perineal ultrasound (4D TPUS). The study will also investigate whether improvements in ultrasound-derived levator hiatal dimensions and pelvic floor relaxation are associated with clinically meaningful reductions in chronic pelvic pain.
Interventions
- Device Pulsed Electromagnetic Field Therapy
PEMF will be applied using a low-frequency pulsed electromagnetic stimulation device with sinusoidal waveform output targeting the lower abdominal and pelvic regions. Treatment sessions will be administered three times weekly for 8 consecutive weeks, with each session lasting approximately 20 minutes. Treatment parameters will include pulsed frequency ranging from 10 Hz, magnetic field intensity ranging from 2 mT, and pulse duration ranging from 250 microseconds. Standard medical care include st - Device Sham pulsed electromagnetic field therapy
Participants in this group will receive sham pulsed electromagnetic field therapy sessions in addition to stable standard medical care. The sham device will appear identical to the active device in shape, sound, and operating indicators without delivering therapeutic electromagnetic output. Session duration, participant positioning, and treatment frequency will match those of the experimental group.
Primary outcome measures
- Endometriosis Health Profile-30 (EHP-30) questionnaire [Time frame: Baseline, 8 weeks and at 3-month follow-up.]
Secondary outcome measures (2)
- Trans-perineal Ultrasound Assessment [Time frame: Baseline, 8 weeks and 3-month follow-up.]
- Pain Intensity scale (VAS) [Time frame: Baseline, 8 weeks and 3-month follow-up.]
Eligibility criteria
Inclusion criteria
- Women aged 18 to 45 years
- Clinically, radiologically, or laparoscopically diagnosed endometriosis
- Chronic pelvic pain persisting for at least 6 months
- Stable pharmacological or hormonal treatment for at least 3 months before enrollment
- Ability to understand study procedures and provide written informed consent
Exclusion criteria
- Pregnancy or planned pregnancy during the study period
- History of gynecological or pelvic malignancy
- Active pelvic inflammatory disease or acute pelvic infection
- Implanted electronic medical devices such as pacemakers or neurostimulators
- Previous pelvic surgery within the past 6 months
- Participation in another clinical trial during the previous 3 months
- Neurological, rheumatological, or severe musculoskeletal disorders affecting assessment procedures
- Contraindications to electromagnetic therapy
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Double blind
- Primary purpose
- Treatment
Study locations
Egypt · 1 center
- Outpatient clinic, faculty of Physical Therapy, Beni Suef University — Banī Suwayf
Identifiers
NCT: NCT07592403 · PEMF IN ENDOMETRIOSIS 2026